Search Results - "Shafer, F"

Laboratory variability in the diagnosis of type 2 VWD variants by DiGiandomenico, Stefanie, Christopherson, Pamela A., Haberichter, Sandra L., Abshire, Thomas C., Montgomery, Robert R., Flood, Veronica H., Valentino, L., Abshire, T., Dunn, A., Bennett, C., Lusher, J., Rajpurkar, M., Hoots, W. K., Brown, D., Shapiro, A., Paola, J. Di, Lentz, S., Gill, J., Leissinger, C., Ragni, M., Hord, J., Manco‐Johnson, M., Ma, A., Boggio, L., Sharathkumar, A., Gruppo, R., Kerlin, B., Journeycake, J., Kulkarni, R., Mahoney, D, Mathias, L., Bedros, A., Diamond, C., Neff, A., Paroskie, A., DiMichele, D., Giardina, P., Cohen, A., Paidas, M., Werner, E., Matsunaga, A., Singer, T., Tarantino, M., Roberts, J., Shafer, F., Konkle, B., Cuker, A., Kouides, P., Stein, D., Manco‐Johnson, M., Dunn, A., Bennett, C., Journeycake, J., Lusher, J., Rajpurkar, M., Shapiro, A., Lentz, S., Lillicrap, D., James, P., Leissinger, C., Roberts, J., Ragni, M.

“…Essentials Patients with von Willebrand disease were enrolled in our study. Type 2 VWD diagnoses were based on original test results. Repeat evaluation…”
Get full text

P1532: SUTIMLIMAB AFTER PRIOR RITUXIMAB USE IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): POOLED POST‐HOC ANALYSES FROM THE CARDINAL AND CADENZA TRIALS by Röth, A., Karaouni, A., Msihid, J., Hemim, I., Joly, F., Shafer, F., Sourdille, T., Hill, Q.

Get full text

Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy by Shafer, F., Smith, L., Vendetti, N., Rendo, P., Carr, M.

“…Summary Spontaneous haemorrhage in patients with haemophilia is generally considered to occur randomly and without a predictable temporal or seasonal pattern;…”
Get full text

S304: SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT‐REPORTED OUTCOMES IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2 YEAR FOLLOW‐UP FROM THE CARDINAL STUDY by Röth, A., Broome, C. M., Barcellini, W., Henrik Anderson Tvedt, T., Miyakawa, Y., D'Sa, S., Cella, D., Joly, F., Wang, J., Sourdille, T., Shafer, F., Wardęcki, M., Weitz, I. C.

Get full text

P1538: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9‐WEEK WASHOUT PERIOD IN PHASE 3 CARDINAL STUDY (NCT03347396) by Röth, A., Barcellini, W., D'Sa, S., Miyakawa, Y., Broome, C. M., Michel, M., Kuter, D. J., Jilma, B., Tvedt, T. H. A., Weitz, I. C., Sourdille, T., Wang, J., Vagge, D. S., Kralova, K., Shafer, F., Wardecki, M., Lee, M., Berentsen, S.

Get full text

S285: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2‐YEAR FOLLOW‐UP FROM THE CARDINAL STUDY by Röth, A., Barcellini, W., D'Sa, S., Miyakawa, Y., Broome, C. M., Michel, M., Kuter, D. J., Jilma, B., Tvedt, T. H. A., Weitz, I. C., Sourdille, T., Wang, J., Vagge, D. S., Kralova, K., Shafer, F., Wardecki, M., Lee, M., Berentsen, S.

Get full text

Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease: A Randomized Controlled Trial by Orringer, Eugene P, Casella, James F, Ataga, Kenneth I, Koshy, Mabel, Adams-Graves, Patricia, Luchtman-Jones, Lori, Wun, Ted, Watanabe, Masayo, Shafer, Frank, Kutlar, Abdullah, Abboud, Miguel, Steinberg, Martin, Adler, Brian, Swerdlow, Paul, Terregino, Carol, Saccente, Suzanne, Files, Beatrice, Ballas, Samir, Brown, Robert, Wojtowicz-Praga, Slawomir, Grindel, J. Michael

“…CONTEXT Sickle cell disease (SCD) can cause severe painful episodes that are often thought to be caused by vaso-occlusion. The current therapy for these…”
Get full text

Acculturation and Maternal Health Behaviors: Findings from the Massachusetts Birth Certificate by HAWKINS, Summer Sherburne, GILLMAN, Matthew W, SHAFER, Emily F, COHEN, Bruce B

“…Although prior studies have shown disparities in maternal health behaviors according to race/ethnicity and acculturation, whether these patterns are evident…”
Get full text

Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors by Arkin, S, Blei, F, Fetten, J, Foulke, R, Gilchrist, G S, Heisel, M A, Key, N, Kisker, C T, Kitchen, C, Shafer, F E, Shah, P C, Strickland, D

“…This open-label, emergency-use study evaluated the efficacy and safety of activated human coagulation factor VIIa (recombinant) (rFVIIa) (NovoSeven; Novo…”
Get more information

Identification of Microdeletions Spanning the Diamond-Blackfan Anemia Locus on 19q13 and Evidence for Genetic Heterogeneity by Gustavsson, Peter, Garelli, Emanuela, Draptchinskaia, Natalia, Ball, Sarah, Willig, Thiébaut-Noël, Tentler, Dimitri, Dianzani, Irma, Punnett, Hope H., Shafer, Frank E., Cario, Holger, Ramenghi, Ugo, Glomstein, Anders, Pfeiffer, Rudolf A., Goringe, Andy, Olivieri, Nancy F., Smibert, Elizabeth, Tchernia, Gil, Elinder, Göran, Dahl, Niklas

“…Diamond-Blackfan anemia (DBA) is a rare pure red-cell hypoplasia of unknown etiology and pathogenesis. A major DBA locus has previously been localized to…”
Get full text

Acculturation and Maternal Health Behaviors by Hawkins, Summer Sherburne, PhD, Gillman, Matthew W., MD, Shafer, Emily F., PhD, Cohen, Bruce B., PhD

“…Background Although prior studies have shown disparities in maternal health behaviors according to race/ethnicity and acculturation, whether these patterns are…”
Get full text

Crucial role for the VWF A1 domain in binding to type IV collagen by Flood, Veronica H., Schlauderaff, Abraham C., Haberichter, Sandra L., Slobodianuk, Tricia L., Jacobi, Paula M., Bellissimo, Daniel B., Christopherson, Pamela A., Friedman, Kenneth D., Gill, Joan Cox, Hoffmann, Raymond G., Montgomery, Robert R.

“…Von Willebrand factor (VWF) contains binding sites for platelets and for vascular collagens to facilitate clot formation at sites of injury. Although previous…”
Get full text

PB1458 Thromboembolic (TE) Events in Cold Agglutinin Disease (CAD): Post-Hoc Analysis PRE- and ON-Sutimlimab Treatment in the Phase 3 CARDINAL and CADENZA Studies by Röth, A., Ueda, Y., McCrae, K., Khan, U., Kralova, K., Wardecki, M., Shafer, F., Yoo, R., Broome, C.

Get full text

Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program by Christopherson, Pamela A., Haberichter, Sandra L., Flood, Veronica H., Perry, Crystal L., Sadler, Brooke E., Bellissimo, Daniel B., Di Paola, Jorge, Montgomery, Robert R., Abshire, T, Weiler, H, Lillicrap, D, James, P, O’Donnell, J, Ng, C, Bennett, C, Sidonio, R, Manco‐Johnson, M, Journeycake, J, Zia, A, Lusher, J, Rajpurkar, M, Shapiro, A, Lentz, S, Gill, J, Leissinger, C, Ragni, M, Tarantino, M, Roberts, J, Hord, J, Strouse, J, Ma, A, Valentino, L, Boggio, L, Sharathkumar, A, Gruppo, R, Kerlin, B, Kulkarni, R, Green, D, Hoots, K, Brown, D, Mahoney, D, Mathias, L, Bedros, A, Diamond, C, Neff, A, DiMichele, D, Giardina, P, Cohen, A, Paidas, M, Werner, E, Matsunaga, A, Shafer, F, Konkle, B, Cuker, A, Kouides, P, Stein, D

“…Background Type 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by the absence of von Willebrand factor (VWF). Objectives As part…”
Get full text

Universal screening for hemoglobinopathies using high-performance liquid chromatography: clinical results of 2.2 million screens by Lorey, F, Cunningham, G, Shafer, F, Lubin, B, Vichinsky, E

“…In screening for hemoglobinopathies, high-performance liquid chromatography (HPLC) achieves excellent sensitivity and specificity, while adding the very…”
Get full text

An acquired inhibitor to factor X in a pediatric patient with extensive burns by MATSUNAGA, A. T, SHAFER, F. E

“…An acquired inhibitor to factor X is an uncommon clinical finding in the pediatric population. We report the development of this type of inhibitor in a…”
Get full text

Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients by BLANCHETTE, V. S., SHAPIRO, A. D., LIESNER, R. J., HERNÁNDEZ NAVARRO, F., WARRIER, I., SCHROTH, P. C., SPOTTS, G., EWENSTEIN, B. M.

“…Background: The pharmacokinetics of factor VIII replacement therapy in preschool previously treated patients (PTPs) with hemophilia A have not been well…”
Get full text

New advances in the pathophysiology and management of sickle cell disease by Shafer, F E, Vichinsky, E

“…The formation of the sickle cell hemoglobin polymer associated with deoxygenation of the sickle erythrocyte is a complex process. There are also many…”
Get more information

A capillary electrophoresis technique for evaluating botulinum neurotoxin B light chain activity by Adler, Michael, Shafer, Harlan F, Manley, Heather A, Hackley, Jr, Brennie E, Nicholson, James D, Keller, James E, Goodnough, Michael C

“…Botulinum neurotoxin B (BoNT/B) produces muscle paralysis by cleaving synaptobrevin/vesicle-associated membrane protein (VAMP), an 18-kDa membrane-associated…”
Get full text

Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program by Shafer, F E, Lorey, F, Cunningham, G C, Klumpp, C, Vichinsky, E, Lubin, B

“…In this article we describe the success of a unique newborn screening program for sickle cell disease and other hemoglobinopathies. We will present and discuss…”
Get full text